載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$3.17
−US$0.20 · -5.93%
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
前收盤價
US$3.17
−US$0.20 · -5.93%
盤後
US$3.23
+US$0.06 · +1.89%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日內區間
目前US$3.17
52週區間
目前US$3.17
盤中時間採用ET。市場資料可能有所延遲。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日內區間
目前US$3.17
52週區間
目前US$3.17
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 405.5萬 USD | 188.1萬 USD | 150.3萬 USD | 95.8萬 USD | 219.8萬 USD |
| 銷貨成本 | 386.5萬 USD | 114.1萬 USD | 109萬 USD | 97.6萬 USD | 77.8萬 USD |
| 毛利 | 19萬 USD | 74萬 USD | 41.3萬 USD | −1.8萬 USD | 142萬 USD |
| 研究與開發 | 1590萬 USD | 983.9萬 USD | 929.4萬 USD | 730.1萬 USD | 503.5萬 USD |
| 銷售、一般及管理費用 | 1697.6萬 USD | 1378.5萬 USD | 1328.5萬 USD | 2153.3萬 USD | 2039.2萬 USD |
| 營業費用 | 3076.8萬 USD | 6178.1萬 USD | 2554.9萬 USD | 1797.9萬 USD | 5514.5萬 USD |
| 利息支出 | 10.9萬 USD | 8.4萬 USD | 5.2萬 USD | 8.3萬 USD | 20.9萬 USD |
| 折舊和攤銷 | 219.7萬 USD | 156.4萬 USD | 168萬 USD | 522萬 USD | 420.5萬 USD |
| 營業利益 | −3057.8萬 USD | −6104.1萬 USD | −2513.6萬 USD | −1799.7萬 USD | −5372.5萬 USD |
| 淨利 | −5022.2萬 USD | −6066.3萬 USD | −2778.1萬 USD | −7290.2萬 USD | −6409.7萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$9.75
上漲空間 207.57%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年7月25日 | 1:20 | — | — |
已生效 2023年7月25日
1:20
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
